These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36586152)

  • 1. Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).
    Dobischok S; Metcalfe R; Matzinger E; Palis H; Marchand K; Harrison S; MacDonald S; Byres D; Schechter M; Bansback N; Oviedo-Joekes E
    Int J Drug Policy; 2023 Feb; 112():103948. PubMed ID: 36586152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best-worst scaling task.
    Metcalfe RK; Dobischok S; Bansback N; MacDonald S; Byres D; Lajeunesse J; Harrison S; Koch B; Topping B; Brock T; Foreman J; Schechter M; Oviedo-Joekes E
    Addiction; 2024 Jul; ():. PubMed ID: 39054406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study.
    Dobischok S; Metcalfe RK; Matzinger EA; Lock K; Harrison S; MacDonald S; Amara S; Schechter MT; Bansback N; Oviedo-Joekes E
    Patient Prefer Adherence; 2022; 16():3405-3413. PubMed ID: 36582266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clients' experiences on North America's first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study.
    Oviedo-Joekes E; Dobischok S; Carvajal J; MacDonald S; McDermid C; Klakowicz P; Harrison S; LaJeunesse J; Chow N; Brown M; Gill S; Schechter M
    BMC Health Serv Res; 2023 May; 23(1):553. PubMed ID: 37237256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "As long as that place stays open, I'll stay alive": Accessing injectable opioid agonist treatment during dual public health crises.
    Jaffe K; Blawatt S; Lehal E; Lock K; Easterbrook A; MacDonald S; Harrison S; Lajeunesse J; Byres D; Schechter M; Oviedo-Joekes E
    Harm Reduct J; 2023 Apr; 20(1):51. PubMed ID: 37060027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment.
    Marchand K; Foreman J; MacDonald S; Harrison S; Schechter MT; Oviedo-Joekes E
    Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):7. PubMed ID: 31959189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants.
    Fox AD; Riback L; Perez-Correa A; Ohlendorf E; Ghiroli M; Behrends CN; López-Castro T
    Subst Use Addctn J; 2024 Jan; 45(1):44-53. PubMed ID: 38258851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Injectable opioid agonist treatment: An evolutionary concept analysis.
    Haines M; O'Byrne P
    Res Nurs Health; 2021 Aug; 44(4):664-671. PubMed ID: 33993526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs.
    Ohlendorf E; Perez-Correa A; Riback L; Ghiroli M; Lopez-Castro T; Fox AD
    J Addict Med; 2023 May-Jun 01; 17(3):e148-e155. PubMed ID: 37267166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans.
    Eydt E; Glegg S; Sutherland C; Meador K; Trew M; Perreault M; Goyer MÈ; Le Foll B; Turnbull J; Fairbairn N
    CMAJ Open; 2021; 9(1):E115-E124. PubMed ID: 33622764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multi-methods and longitudinal study of patients' perceptions in injectable opioid agonist treatment: Implications for advancing patient-centered methodologies in substance use research.
    Marchand K; Palis H; Guh D; Lock K; MacDonald S; Brissette S; Marsh DC; Harrison S; Schechter MT; Oviedo-Joekes E
    J Subst Abuse Treat; 2022 Jan; 132():108512. PubMed ID: 34098207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.
    Bozinoff N; Tardelli VS; Rubin-Kahana DS; Le Foll B
    Harm Reduct J; 2022 Oct; 19(1):113. PubMed ID: 36229831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "They Talk to Me Like a Person" Experiences of People in an Injectable Opioid Agonist Treatment Program: A Qualitative Interpretive Description.
    Jackson J; Colborne M; Gadimova F; Kennedy MC
    J Addict Nurs; 2023 Jul-Sep 01; 34(3):166-172. PubMed ID: 37669335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Patients' Perceptions on Injectable Opioid Agonist Treatment: Influences on Treatment Initiation and Implications for Practice.
    Friedmann Z; Binder A; Kinkel HT; Kühner C; Zsolnai A; Mick I
    Eur Addict Res; 2024; 30(1):32-42. PubMed ID: 38104539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in daily dose in open-label compared to double-blind: The role of clients' expectations in injectable opioid agonist treatment.
    Blawatt S; Arreola LAG; Magel T; MacDonald S; Harrison S; Schechter MT; Oviedo-Joekes E
    Addict Behav Rep; 2023 Jun; 17():100490. PubMed ID: 37124402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series.
    Brar R; Fairbairn N; Colizza K; Ryan A; Nolan S
    J Addict Med; 2021 Apr; 15(2):163-166. PubMed ID: 32769776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with injectable hydromorphone: Comparing retention in double blind and open label treatment periods.
    Oviedo-Joekes E; Palis H; Guh D; Marchand K; Brissette S; Harrison S; MacDonald S; Lock K; Anis AH; Marsh DC; Schechter MT
    J Subst Abuse Treat; 2019 Jun; 101():50-54. PubMed ID: 31174713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study.
    Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K
    Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series.
    Patricelli CJ; Chai J; Gordon S; Gouin IJ; Carter N; Stewart K; Paquette V; Urbanoski K; Albert A
    J Addict Med; 2023 Jul-Aug 01; 17(4):431-438. PubMed ID: 37579103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Supervised on-site dosing in injectable opioid agonist treatment-considering the patient perspective. Findings from a cross-sectional interview study in two German cities.
    Friedmann Z; Kinkel HT; Kühner C; Zsolnai A; Mick I; Binder A
    Harm Reduct J; 2023 Nov; 20(1):162. PubMed ID: 37915058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.